Skip to main content

Table 3 Univariate & multivariate analysis of risk factor for overall pulmonary toxicity

From: Effect of dose rate on pulmonary toxicity in patients with hematolymphoid malignancies undergoing total body irradiation

  Univariate analysis Multivariate analysis
SHR 95% CI P-value SHR 95% CI P-value
Group
 Reduced dose rate group 1 (ref)      
 Conventional dose rate group 1.86 0.93–3.71 0.078 2.61 1.26–5.40 0.010
Total dose (Gy) 1.19 0.94–1.51 0.156 1.38 1.04–1.83 0.025
Daily dose (Gy)
 Daily dose < 3 1 (ref)      
 Daily dose ≥3 0.67 0.36–1.25 0.205    
Women 1.23 0.70–2.18 0.471
Age at TBI (year) 1.00 0.98–1.02 0.723
Cancer type
 ALL 1 (ref)      
 AML 1.47 0.81–2.67 0.210
 Others 1.17 0.56–2.44 0.682
Unrelated donor 1.22 0.70–2.10 0.482
Conditioning regimen
 Cyclophosphamide 1 (ref)      
 Cy + othera 1.92 0.76–4.81 0.165 2.86 1.11–7.38 0.029
 Othersb 1.06 0.40 – 2.81 0.911 1.60 0.54–4.73 0.394
Prior chemotherapy regimens
 1 1 (ref)      
 2 0.61 0.29–1.30 0.200
  ≥ 3 1.32 0.69–2.52 0.409
  1. P-by Fine-Gray
  2. SHR Sub-hazard ratios, ALL Acute lymphoblastic leukemia, AML Acute myeloid leukemia, GVHD Graft-versus-host disease
  3. a other: cytarabine, fludarabine, etoposide
  4. b others: cytarabine/fludaraibine, busulfan/fludarabine/etoposide, melphalan, melphalan/fludarabine, thiotepa